Evonik Expanding Global Isophorone and Isophorone Diamine Capacities
News Nov 15, 2013
Evonik Industries is significantly expanding its global isophorone (IP) and isophorone diamine (IPD) capacities by funding an investment of more than €100 million in Shanghai, China.
“We're investing in China, because we are committed to the growth region Asia. As a world leader in isophorone-based products, we will continue to further consolidate and expand our position in this chemistry," says Dr. Ulrich Küsthardt, President of Evonik’s Coating & Additives Business Unit.
With the Group’s expansion strategy it aims to support the growth ambitions of key customers in Asia and around the world. Proximity to consumers in this growing market will translate into improved local service, shorter lead times, and faster responses to changes in demand. “Our aim in building the plants in Shanghai— at the company’s existing multi-user site—is to supply our Asian customers with the same high-quality products they are used to from our plants in Europe and the USA, now from a plant in the region," says Gerd Brand, Senior Vice President and Head of Crosslinkers Business Line.
Evonik has proven expertise in the manufacturing of products based on isophorone, backed up by fifty years of experience. The Group is a global market leader in isophorone chemistry with production facilities in Herne, Marl (Germany), Mobile, Alabama (USA) and Antwerp (Belgium). Its products are known worldwide under the brand names of VESTAMIN®, VESTANAT®, VESTAGON® and VESTASOL®.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018